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Glioblastoma, the most aggressive form of primary brain tumor, is predominantly assessed
with gadolinium-enhancedT1-weighted (T1Gd) andT2-weighted magnetic resonance imag-
ing (MRI). Pixel intensity enhancement on the T1Gd image is understood to correspond
to the gadolinium contrast agent leaking from the tumor-induced neovasculature, while
hyperintensity on theT2/FLAIR images corresponds with edema and infiltrated tumor cells.
None of these modalities directly show tumor cells; rather, they capture abnormalities in
the microenvironment caused by the presence of tumor cells. Thus, assessing disease
response after treatments impacting the microenvironment remains challenging through
the obscuring lens of MR imaging. Anti-angiogenic therapies have been used in the treat-
ment of gliomas with spurious results ranging from no apparent response to significant
imaging improvement with the potential for extremely diffuse patterns of tumor recurrence
on imaging and autopsy. Anti-angiogenic treatment normalizes the vasculature, effectively
decreasing vessel permeability and thus reducing tumor-induced edema, drastically alter-
ing T2-weighted MRI. We extend a previously developed mathematical model of glioma
growth to explicitly incorporate edema formation allowing us to directly characterize and
potentially predict the effects of anti-angiogenics on imageable tumor growth. A compari-
son of simulated glioma growth and imaging enhancement with and without bevacizumab
supports the current understanding that anti-angiogenic treatment can serve as a surro-
gate for steroids and the clinically driven hypothesis that anti-angiogenic treatment may
not have any significant effect on the growth dynamics of the overall tumor cell popu-
lations. However, the simulations do illustrate a potentially large impact on the level of
edematous extracellular fluid, and thus on what would be imageable on T2/FLAIR MR.
Additionally, by evaluating virtual tumors with varying growth kinetics, we see tumors with
lower proliferation rates will have the most reduction in swelling from such treatments.
Keywords: glioma, edema, mathematical model, anti-angiogenic therapy
INTRODUCTION
Glioblastoma Multiforme (GBM) is a highly aggressive and inva-
sive primary brain tumor. The standard treatment protocol is
to surgically remove as much of the tumor as is reasonably
safe, followed by a combination of chemotherapy with radia-
tion. Despite aggressive treatment, the prognosis remains poor
with a median survival time of 14 months (Stupp et al., 2005).
The inability to accurately determine the extent of diffuse tumor
cell infiltration of the normal brain affects the ability to assess
response to treatment through clinical imaging, confounding clin-
ical progress. Currently, clinicians rely primarily on three magnetic
resonance imaging (MRI) modalities to monitor the development
of the tumor, the T2 weighting, FLAIR, and T1 weighting with
gadolinium contrast enhancement (T1Gd) sequences illustrated
in Figure 1. However, it is known that none of these sequences
are able to show the entire extent of the malignant cells (Silbergeld
and Chicoine, 1997), since the abnormal regions highlighted in the
MR images are as dependent on the microenvironment around
the disease, particularly the vasculature, as on the tumor cells
themselves.
Increased vasculature is a primary hallmark of GBM, and while
angiogenesis is a hallmark of cancer in general, there are some
important factors that separate GBMs from other tumors. First,
the glioma cells inhabit an organ that is highly vascularized in
its native state. Second, glioma cells are diffusely invasive and are
known to co-opt the existing vasculature and migrate and grow
along the vessels (Holash et al., 1999; Leenders et al., 2002). Never-
theless, GBMs can form hypoxic regions, often leading to regions
of necrosis, and thus, downstream of this hypoxic signaling, emit
an abnormally large amount of angiogenic factors such as vas-
cular endothelial growth factor (VEGF) for the recruitment of
additional vasculature, analogous to observations in solid tumors
(Kerbel, 2000). This process results in the vasculature developing
abnormally large vessel radial sizes and, unique to the brain, results
in a breakdown of the blood brain barrier in the tumor region.
FEATURES CHARACTERIZING MR IMAGING OBSERVATION
In the case of GBM, the enhancing abnormalities on all of the
primary MR imaging modalities, T1Gd, T2, and FLAIR primarily
result from a compromised blood brain barrier. The T1Gd image
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FIGURE 1 | Illustration of primary imaging modalities. The T1Gd image
will show enhancement where the contrast agent has been able to diffuse
into the extracellular space where the blood brain barrier has been
compromised due to tumor-induced neo-angiogenesis. The T2-weighted
and FLAIR images are associated with edema or swelling; FLAIR is
different from T2 in that the signal from the cerebral spinal fluid (CSF) is
removed. In the case of GBM, the non-CSF T2/FLAIR enhancement is
primarily vasogenic edema, defined as fluid originating from blood vessels
that accumulates around cells (Marmarou, 2007). The fluid leaves the
vessels due to pressure and osmotic gradients induced by the breakdown
in the blood brain barrier.
signal is enhanced where the contrast agent has been able to leak
into the extracellular space through breakdowns in the blood brain
barrier due to tumor-induced neo-angiogenesis. The T2-weighted
and FLAIR images show edema or swelling; FLAIR is different from
T2 in that the signal from the cerebral spinal fluid (CSF) is inverted.
In the case of GBM, the non-CSF T2/FLAIR hyperintense signal
is primarily vasogenic edema, defined as fluid originating from
blood vessels that accumulates around cells (Marmarou, 2007).
The fluid leaves the vessels due to pressure and osmotic gradients
induced by the breakdown in the blood brain barrier. Thus, whilst
changes in any primary imaging modality (T1Gd or T2/FLAIR)
are often interpreted as corresponding to changes in tumor cell
density, they may be artifacts of MR imaging.
THE ROLE OF ANTI-ANGIOGENICS IN GBM
The concept of anti-angiogenic treatment for cancer has been
popular ever since the landmark paper by Folkman (1971) stat-
ing that malignant tumors were angiogenesis-dependent and has
been used with some success for other solid tumors in combina-
tion with chemotherapy (Hurwitz et al., 2004; Sandler et al., 2006).
Since a defining hallmark of GBM is increased vasculature through
endothelial cell proliferation (Louis et al., 2007), this disease seems
like an obvious candidate for vascular targeting treatment. How-
ever, the differences between the vasculature in GBMs and other
solid tumors produce different treatment effects. In GBMs, one of
the effects of anti-angiogenic treatments is to, at least transiently,
repair the blood brain barrier and allow the vessels to return to
their normal radial size, increasing their efficiency (Jain, 2005;
Batchelor et al., 2007) – referred to as vascular normalization.
Ostensibly, this improved efficiency of the vasculature is not the
desired impact, though it may help in delivery of other therapeutic
agents.
More concerning, however, is that this normalization may
directly impact the efficacy of the MR imaging. It is possi-
ble for glioma patients with enhancing lesions on T1Gd and
T2/FLAIR imaging to have decreased enhancement within a day
of anti-angiogenic treatment (Batchelor et al., 2007; Norden et al.,
2008), as illustrated by patients 1 and 2 in Figure 2, but upon
stopping treatment, the imageable lesion is even larger and more
disperse than before (Iwamoto et al., 2009). However, responses
are varied; a patient may see no deflection in growth but faster
growth after treatment, such as the third patient in Figure 2, or
see stabilized disease returning to the previous growth patterns
after treatment, as illustrated by the fourth patient in Figure 2.
These patients were consented to this study with approval by the
local institutional review board at either the University of Wash-
ington or the University of California, Los Angeles, and their
relevant demographic and therapeutic information is given in
Table 1. These conundrums have led to two hypotheses: first,
anti-angiogenic treatment has minimal cytotoxic effect but does
influence the imaging so that the tumor cannot be effectively visu-
alized, and second, that the treatment may be selecting for a more
aggressively invasive phenotype (Verhoeff et al., 2009; Keunen
et al., 2011).
Previous studies have shown the use of anti-angiogenic drugs,
specifically bevacizumab (Avastin), tends to increase progression-
free survival and reduce symptoms of recurrent GBMs, but they
have failed to consistently show a significant increase in over-
all survival and there is concern that the measured radiographic
responses do not reflect changes in tumor cell counts (Verho-
eff et al., 2009; Deming, 2012). Additionally, animal studies have
revealed that treatment with anti-angiogenic drugs may be cre-
ating an environment favorable for local invasion and metastasis
(Ebos et al., 2009; Pàez-Ribes et al., 2009). Even though there is
a lack of significant evidence for increased overall survival after
bevacizumab, and it is possible that treatment selects for a more
invasive phenotype, the increase in quality of life for some of the
patients, due to the relief from edema-related symptoms, means
anti-angiogenic therapy is an attractive and relevant treatment
option. However, the inability to determine a priori which patients
will receive more benefit than harm from anti-angiogenic therapy
ultimately keeps clinicians wary (Deming, 2012).
In this paper, we aim to illustrate how a previous mathematical
model of glioma growth can be extended to explicitly incorporate
edema formation allowing us to directly characterize and poten-
tially predict the effects of anti-angiogenics on imageable tumor
growth. The ultimate goal of this model is to help the treatment
planning process by identifying exactly those patients that would
receive the most benefit from anti-angiogenic treatment.
MATERIALS AND METHODS
THE PROLIFERATION-INVASION-HYPOXIA-NECROSIS-ANGIOGENESIS-
EDEMA MODEL
Over the last decade we have made a significant effort toward
the development of patient specific mathematical models of GBM
that are able to capture the growth kinetics of individual patients
(Swanson, 1999; Swanson et al., 2000, 2002a,b; Harpold et al., 2007;
Rockne et al., 2010). The simplest form of the model, referred
to as the Proliferation-Invasion (PI) model is based on patient
specific net rates of proliferation and invasion and has been suc-
cessful in predicting untreated growth rates for individual patients
(Harpold et al., 2007) and providing predictions of outcomes fol-
lowing surgical resections (Swanson et al., 2003), chemotherapy
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FIGURE 2 | Four patients with varying imageable responses to
anti-angiogenic treatment. Treatment period indicated with gray box
on radius plots. (A) Patient 1: A 48-year-old male with Grade III glioma
is seen to have significant reduction of enhancing lesion during
treatment but recurs almost immediately after treatment is stopped,
(B) Patient 2: a 55-year-old male with GBM initially responds to
treatment but even while being treated the enhancing region is seen
to enlarge again, (C) Patient 3: a 61-year-old male with GBM seems to
have no response to treatment and the enhancing region seems to
grow faster after treatment, and (D) Patient 4: a 66-year-old female
with GBM has imaging stabilized during treatment, but enhancing
region begins growing again once treatment is stopped.
Table 1 | Demographic and treatment information corresponding to patients in Figure 2.
Age Sex Grade Race XRT dose
(cGy)
Concurrent
TMZ
Bev given at
recurrence
Concurrent
therapies with Bev
Patient 1 48 M III Caucasian Given, but unknown dosage Y Y Irinotecan, dexamethasone
Patient 2 55 M IV Caucasian 6000 Y Y Carboplatin
Patient 3 61 M IV Unknown 6000 Y Y Irinotecan
Patient 4 66 F IV Caucasian 6120 Y Y Irinotecan
(Swanson et al., 2002a,b, 2003), and radiation (Rockne et al., 2010),
while also providing insight into glioma ontogeny (Bohman et al.,
2010).
A MATHEMATICAL MODEL OF THE ANGIOGENIC CASCADE IN
GLIOBLASTOMA
The Proliferation-Invasion-Hypoxia-Necrosis-Angiogenesis
(PIHNA) model first discussed in Swanson et al. (2011) incorpo-
rates the angiogenic cascade and characterizes malignant gliomas
with relative proportions of well-oxygenated “normoxic” tumor
cells, (c), poorly oxygenated hypoxic tumor cells, (h), necrotic cells,
(n), and vascular, or endothelial cells, (v), along with a generic pop-
ulation of angiogenic factors, (a) (Swanson et al., 2011). In words,
it assumes the level of nutrients present in the local microenviron-
ment, as inferred from the number of vasculature cells, determines
whether the present tumor cells will exhibit normoxic or hypoxic
phenotypes. That is, if there is a sufficient level of nutrients present,
the cells will remain normoxic, but if the nutrient level falls below a
given threshold, the cells will become hypoxic. If the nutrients pro-
vided by the vasculature fall below an even lower threshold value,
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the hypoxic cells will undergo necrosis, at a rate of αh (1/year)
and remain in the necrotic cell population. Normoxic tumor cells
are allowed to move (invade) and divide while, due to restricted
amounts of nutrients, the hypoxic cells are only allowed to move.
The hypoxic cells produce a large amount of angiogenic factors
which ultimately cause an increase in the number of vasculature
cells. The system is described with a mathematical model com-
posed of the following five coupled reaction-diffusion equations:
∂c
∂t
=
Net dispersal of normoxic
glioma cells︷ ︸︸ ︷
∇ · (D (x) (1− T )∇c) +
Net proliferation of normoxic
glioma cells︷ ︸︸ ︷
ρ c (1− T )
+
Conversion of hypoxic
to normoxic︷ ︸︸ ︷
γ h V −
Conversion of normoxic
to hypoxic︷ ︸︸ ︷
β c (1− V )
−
Conversion of normoxic
to necrotic︷ ︸︸ ︷
αn n c
∂h
∂t
=
Dispersal of hypoxic
glioma cells︷ ︸︸ ︷
∇ · (D (x) (1− T )∇h)−
Conversion of hypoxic
to normoxic︷ ︸︸ ︷
γ h V
+
Conversion of normoxic
to hypoxic︷ ︸︸ ︷
β c (1− V ) −
Conversion of hypoxic
to necrotic︷ ︸︸ ︷
(αhh (1− T )+ αnnh)
∂n
∂t
=
Conversion of hypoxic, normoxic, and vasculature to necrotic︷ ︸︸ ︷
αhh (1− V )+ αnn (c + h + v)
∂v
∂t
=
Dispersal of
vasculature︷ ︸︸ ︷
∇ · (Dv (x) (1− T )∇v)+
Net proliferation
of vasculature︷ ︸︸ ︷
µ
a
Km + a v (1− T )
−
Conversion of vasculature
to necrotic︷ ︸︸ ︷
αnn v
∂a
∂t
=
Net dispersal
of angiogenic factors︷ ︸︸ ︷
∇ · (Da∇a) +
Net production of
angiogenic factors︷ ︸︸ ︷
δc c + δhh
−
Net consumption of
angiogenic factors︷ ︸︸ ︷
qµ
a
Km + a v (1− T )− ωav −
Decay of
angiogenic factors︷︸︸︷
λa .

(1)
In these equations,D(x) is the net rate of invasion (mm2/year).
Glioma cells migrate faster along myelinated axons in the white
matter than in the dense and less structured cortical gray matter.
For this reason, we consider the net rate of invasion as piecewise
constant, with non-zero values in the gray and white matter, Dg
and Dw, respectively, with Dw >Dg, and zero in the regions of
cerebral spinal fluid. Additionally, ρ (1/year) is the net prolifera-
tion rate of the normoxic cells, γ (1/year) and β (1/year) are the
maximum conversion rates between the hypoxic and normoxic
cell populations, αn (1/year) is the rate at which cells undergo
necrosis when in contact with necrotic cells (contact necrosis), αh
(1/year) is the rate of conversion of hypoxic cells to necrotic cells
when nutrient levels fall too low, Dv (mm2/year) is the rate of
dispersal of vasculature cells, estimated from Sherratt and Murray
(1990), Levine et al. (2001) µ (1/year) is the vasculature prolifera-
tion rate, estimated from Xiu et al. (2006), T = (c + h+ n+ v)/K
(dimensionless), where K is the carrying capacity (cells/mm3),
and V = v/(v + c + h) (dimensionless) and is a surrogate for the
local vasculature efficiency. Angiogenic factors are produced by
both normoxic and hypoxic cells with rates δc (1/year) and δh
(1/year) respectively, with δh> δc and are consumed by the vas-
culature for both regular vasculature maintenance [with rate ω
(1/year)] and for vasculature proliferation [with rate q (1/year)].
Finally, the angiogenic factors are assumed to decay over time with
rate λ (1/year) and disperse with rate Dv (mm2/year). Values for
parameters related to the angiogenic factors were derived in part
from work done in Levine et al. (2001), Serini et al. (2003), Mac
Gabhann and Popel (2004). The reader is referred to (Swanson
et al., 2011) for further details.
It is known that GBM tumors are extremely genetically het-
erogeneous both within a single tumor and between different
tumors (Dunn et al., 2012). A large effort has been put forth to
identify subtypes of GBMs by their dominating genotype (Ver-
haak et al., 2010). While the model parameters do not directly
try to capture effects of single mutations, it is our belief that
the dominating genotypes characterizing subtypes of GBMs ulti-
mately result in different net rates of proliferation and invasion
which would be used in our model. For example, pro-neural
tumors are more likely to have the IDH-1 mutation and be sec-
ondary GBMs. In our model, this would manifest as a low-D,
low-ρ tumor which begins as low grade and progresses into higher
grade/malignancy.
In this model, there are different cell populations, normoxic,
hypoxic, and necrotic competing for space and each with differing
phenotypes: normoxic cells proliferating and invading, hypoxic
cells only invading, and necrotic cells which are dead and just
taking up space. Since each cell population is evolving in space
and time, there is an effective spatial heterogeneity of predicted
proliferative activity across space and time which could be analo-
gized to heterogeneous Ki67 labeling across glioma specimens.
Thus, while this model is attempting to capture the overarching
phenotype of different tumors and assumes global constants for
individual tumors, spatial heterogeneity in behavior is possible due
to regional levels of vasculature which may result in hypoxia and/or
necrosis. We also remark the aim of this model is not to predict cell-
level behaviors (ex. Ki67), rather, use information obtained from
routine imaging to quantify and explain imaging scale behavior
and evolution.
The PIHNA model only captures cellular species and angio-
genic factors. While these all have an impact on what is ulti-
mately seen on MR imaging, in and of themselves they are
not sufficient to describe enhancing regions of T2 and T1Gd
MR images. Here we extend the PIHNA model to capture the
imaging responses post anti-angiogenic treatment. To achieve
this, we add to the model one additional element: edema, (l),
to create the merged proliferation-invasion-hypoxia-necrosis-
angiogenesis-edema (PIHNA-E) model. A schematic of the six
species interactions is shown in Figure 3.
A MATHEMATICAL MODEL FOR TUMOR-INDUCED EDEMA FORMATION
Generically, edema refers to a swelling phenomenon. While there
are different types of cerebral edema, in the case of GBM, it is
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FIGURE 3 | Schematic of the PIHNA-E model. The main components of
the model are seen in the flow chart: c represents the normoxic glioma
cells, h the hypoxic gliomas cells, v the vascular endothelial cells, n the
necrotic cells, a, the angiogenic factors, and l the edematous fluid.
Depending on the level of oxygen, normoxic, and hypoxic cells will
undergo phenotypic switching. If oxygen levels fall too far and are not
compensated for by sufficient angiogenesis, the hypoxic cells will undergo
necrosis. Additionally, all cells will undergo necrosis if in contact with
necrotic cells. Both hypoxic and normoxic cells release angiogenic factors
into the extracellular space which recruit additional vasculature to increase
the levels of oxygen. The angiogenic factors are removed from the system
by interaction with vascular cells or natural decay. The local levels of
angiogenic factors are indicative of the local degree of vessel permeability.
Edematous liquid exits the vasculature where the permeability, K trans(a),
allows and enters the extracellular space where it diffuses and will be
removed at rate dl.
almost exclusively vasogenic edema which results from fluid and
protein leakage from the breakdown of the blood brain barrier
(Marmarou, 2007). Over the last few decades, there have been
quite a few attempts to model vasogenic edema (Rapoport, 1978;
Kumagai, 1986; Nagashima et al., 1990) and its associated intersti-
tial pressure and interstitial fluid velocity (Baxter and Jain, 1989,
1990). These models were primarily based on Starling’s equation
which describes fluid exchange between compartments due to
pressure and osmotic gradients. These models are very detailed
and are generally solved on shorter time scales, i.e., a few days ver-
sus months. In our efforts, while we do have interest in the specific
mechanisms, we will take a coarser grained approach allowing us
to approximate the phenomena over longer time scales relevant to
tumor growth kinetics.
To begin, we make the simplifying assumption that the edema
is only composed of fluid which has leaked into the extra-cellular
space and has not yet been reabsorbed into the system. This fluid is
assumed to leak into the extracellular space where the blood brain
barrier has been compromised. From the PIHNA model, we can
approximate these regions along with the degree of permeability
from the local levels of present angiogenic factors. Once the fluid is
in the extra-cellular space it moves via diffusion and is reabsorbed
into the system at a constant rate. This process is written in the
form of a partial differential equation as:
Change in time of fluid︷︸︸︷
∂ l
∂t
=
Fluid diffusion︷ ︸︸ ︷
∇ · (Dl∇l) +
Leakage︷ ︸︸ ︷
Ktrans (a) · (lv − l)−
Drainage︷︸︸︷
δl l .
(2)
Here l is the concentration of edematous fluid, Dl (mm
2/year)
is the diffusion rate of the edematous liquid which would be anal-
ogous to an Apparent Diffusion Coefficient, ADC, value derived
from diffusion-weighted MRI (Moritani, 2009), lv (fluid/mm3)
is the normal level of fluid in the vasculature, δl (1/year) is the
reabsorption rate, and K trans (1/year) is the transmission rate
[analogous to the value K trans measured on dynamic contrast
enhanced MRI (DCE-MRI)], capturing the permeability sur-
face area product per unit volume of tissue (Tofts, 1991) and is
assumed to depend on the level of angiogenic factors, a, present.
Homogeneous Neumann boundary conditions are assumed at the
boundary of the brain to ensure no fluid leaves the brain.
The dependence of the K trans coefficient on the angiogenic
factors is assumed to take a Michaelis–Menten type I form:
Ktrans (a) = Kmax a
a + Khalf (3)
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to reflect that VEGF (also known as vascular permeability factor,
VPF) strongly influences vascular permeability (Bates, 2010). Here
Kmax (1/year) is the maximum possible value of K trans, the value
of which is calibrated to Grade IV gliomas (Patankar et al., 2005),
and K half (angiogenic factors/mm
3) is the concentration of a at
which K trans reaches half of its maximum value. Thus, as the con-
centration of the angiogenic factors increases, the degree of vessel
permeability will also increase until saturated.
MODELING ANTI-ANGIOGENIC TREATMENT
The PIHNA-E model describes the evolution of the tumor and its
microenvironment in an untreated context. By understanding the
premise of how specific therapies are meant to alter the system,
one can also model the effects of various treatments. Here we are
interested in anti-angiogenic treatment and, while there are many
different types of drugs for this action, will focus on the drug
bevacizumab.
Bevacizumab is a drug specifically targeted at the molecule
vascular endothelial growth factor A (VEGF A). This particular
angiogenic factor stimulates the growth of new vessels by binding
with the vascular endothelial growth factor receptor (VEGFR2) on
endothelial cells. Bevacizumab inhibits angiogenesis by binding to
the free molecules of VEGF A and preventing them from binding to
VEGFR2. An unintended consequence of this drug,however, is that
beyond preventing the growth of new vessels, it also “normalizes”
pre-existing vasculature (Jain, 2005; Verhoeff et al., 2009). That
is, once the levels of stimulating angiogenic factors are reduced,
the vessels are able to repair their leakiness and return to a nor-
mal size – making them more efficient nutrient deliverers. In our
model, both of these phenomena can be captured by requiring
higher levels of angiogenic factor to be present to have the same
level of “action” in the contexts of both vessel proliferation and
vessel permeability. Additionally, since the treatment is making
the vessels more efficient, the level of vasculature needed for a cell
to be normoxic will decrease, which we can capture by modify-
ing the cell conversion rates from hypoxic to normoxic and from
normoxic to hypoxic. Treatment is approximated by decreasing
the parameter for conversion from normoxic to hypoxic (β) by a
factor of 10, increasing the parameter for conversion from hypoxic
and normoxic (γ) by a factor of 10, and increasing the required
levels of angiogenic factors for inducing vascular growth and ves-
sel permeability by 2 as supported by the studies in Desjardins
et al. (2007), Zhang et al. (2009). The treatment modification of
β and γ is representative of a dramatic increase in the efficiency
of the blood vessels, though exact changes are not available from
experimental data.
SIMULATIONS OF GLIOBLASTOMA GROWTH AND RESPONSE TO
ANTI-ANGIOGENIC THERAPY
For simplicity, we consider in all simulations here a two-
dimensional tumor growing on one axial slice of the brain, with
the brain geometry defined from the BrainWeb atlas (Cocosco
et al., 1997). The brain is primarily composed of three different
types of matter, CSF, gray matter, and white matter. Glioblastomas
originate in gray or white matter and due to physical barriers will
not enter into the regions of CSF. New mass will often deform
the barriers, a phenomena called mass effect, and while there
are some models that attempt to capture this (Clatz et al., 2005;
Mohamed and Davatzikos, 2005; Hogea et al., 2008), here the brain
is considered a stationary domain.
In all simulations, the domain is taken to be a slice of human
brain embedded in a grid [0, 147] mm× [0, 185] mm and the
equations are spatially discretized on a grid with resolution of
1 mm× 1 mm using first order accurate finite volumes. Time
integration is done with an operator splitter technique utilizing
backward Euler for the diffusion terms and the TR-BDF2 algo-
rithm (Leveque, 2005) for the reaction terms with a time step size
of 1 day. The simulations were initiated with a small amount of
normoxic cells distributed as
c0
(
x , y , t = 0) = 1000∗exp (− (100 [(x − x0)2 + (y − y0)2]))
where (x0, y0)= (103, 83). Vasculature is set at 3% of the cell car-
rying capacity in all gray and white matter based on estimates from
Blinkov and Glezer (1968), and all other quantities in the PIHNA-
E model are initiated to zero. Unless otherwise stated, parameter
values used in simulations for the edema equation are in Table 2,
the additional parameter values are taken as specified in Swanson
et al. (2011).
RESULTS
DECOUPLING IMAGING CHANGES FROM TUMOR RESPONSE
To highlight the real impact of anti-angiogenic treatment as
captured by our model, we chose parameter values that rep-
resent a patient with an aggressive GBM (net invasion rates
Dw= 53 mm2/year andDg= 0.53 mm2/year and net proliferation
rate ρ= 75 1/year) and simulate tumor growth without treatment
(Figure 4) and then compare to tumor growth with treatment
(Figure 5). For comparison to what was done in previous work
(Swanson et al., 2008a, 2011; Rockne et al., 2010), we refer to the
region with total cell density summing to 80% of the cell carry-
ing capacity (K ) to correspond to what would enhance on the
T1Gd, and started treatment when the T1Gd spherically sym-
metric equivalent radius was equal to 1 cm and was terminated
100 days later. This is consistent with a typical size of an abnormal-
ity seen clinically for consideration of anti-angiogenic treatment.
Although treatment length can vary, 100 days is representative of
the length of a typical course of treatment with anti-angiogenics
in human GBM.
Snapshots of the untreated case are shown in Figure 4 with
the analogous snapshots corresponding to the same time points
of the treated tumor being shown in Figure 5. The top row in
both Figures 4 and 5 shows the density of the bulk tumor (the
summed density of all the cell populations: normoxic, hypoxic,
necrotic, and vasculature). The second row shows what the sim-
ulated FLAIR corresponding to the microenvironmental levels of
edematous extracellular fluid. These figures also contain radial
growth plots showing the equivalent spherical radii for the regions
of interest corresponding to the tumor and the edema. The line
representing the bulk tumor is calculated from the volume of tis-
sue containing abnormal cells, normoxic, hypoxic, and necrotic,
at levels greater than or equal to 16% of the carrying capacity,
i.e., a density five times lower than what can be visualized on
T1Gd (Swanson et al., 2008b). The edema radius was defined by
considering the volume containing edematous fluid above 50%
of the fluid level in the capillaries. There is no literature to guide
Frontiers in Oncology | Molecular and Cellular Oncology April 2013 | Volume 3 | Article 66 | 6
Hawkins-Daarud et al. Modeling tumor-associated edema
Table 2 | Parameter values for the edema equation used in all simulations unless stated otherwise in the text.
Parameter Definition Value Reference
K half Michaelis–Menten half-max of response of
ECs to angiogenic factors
5.75e−7 (mmol/cc tissue) Derived from Mac Gabhann and Popel (2004)
Dl Net rate of edematous fluid diffusion 0.77e−3 (mm2/s) Chosen as average ADC value in normal brain
tissue as given in Moritani (2009)
K max Maximum K trans value in response to
angiogenic factors
36 (1/day) Taken to match the maximum K trans value observed
in Grade IV gliomas in Patankar et al. (2005)
δI Edematous fluid reabsorption rate 0.3×K max (1/day) Assumed proportional to vessel permeability
All other parameter values are taken as described in Swanson et al. (2011).
FIGURE 4 | Illustrated here is the comparison of the simulated
disease burden to what would be imageable on a FLAIR MRI
in an untreated context for one set of growth parameters
corresponding to an aggressive GBM. Below the plot shows the
spherically symmetric equivalent radial growth of the regions
containing tumor cells above a threshold and edematous fluid
above a threshold. In the untreated context, these lines are nearly
identical.
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FIGURE 5 | Comparison of the simulated disease burden to what would
be imageable on a FLAIR MRI in a treated context for the same set of
growth parameters as shown in Figure 4. Below the plot shows the
spherically symmetric equivalent radial growth of the regions containing
tumor cells above a threshold and edematous fluid above a threshold. Once
treatment has begun, we see a drop in the levels of edema. Upon termination
of the treatment, the edematous volume is seen to once again increase to
the same size of the volume of tumorous cells.
the choice of the cutoffs for fluid volume constituting T2/FL visi-
ble edema. Thus, cutoffs were chosen to roughly match clinically
observed behavior.
In the untreated case (Figure 4) the radial plot shows the size
of the region impacted by edema evolves very similarly to the size
of the region occupied by the bulk tumor throughout the entire
course of growth. In the treated case (Figure 5), the edema grows at
the same rate as the bulk tumor until the treatment begins at which
point the edema begins to decline. Edema begins to increase again
once the angiogenic factors have been able to accumulate at lev-
els which overcome the impact of the anti-angiogenic drug. Once
treatment is terminated the edema levels rise to again occupy a
region of the same size as the bulk tumor.
These simulations support the hypothesis that anti-angiogenic
treatment may not have a significant effect on the growth dynam-
ics of the overall cell populations, while having a large impact on
the level of edematous extracellular fluid and thus on what would
be imageable on T2/FLAIR MRI. This is also in agreement with
the current understanding that anti-angiogenic treatment serves
as a surrogate to steroids for reducing swelling.
EXPLORING RESPONSE ACROSS TUMOR KINETICS
The virtual control experiment illustrated in Figures 4 and 5 is only
providing insight into tumor/edema response for the case of one
set of tumor growth kinetics. However, the range of radiographic
response patterns seen clinically is broad, a few examples of which
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are shown in Figure 2. Previous work has shown patient specific
values of net proliferation and invasion range over many orders
of magnitude (Tracqui et al., 1995; Harpold et al., 2007). To inves-
tigate if the different types and extents of radiographic responses
could be explained by different underlying tumor growth kinetics,
we simulated tumor growth and the associated edema under treat-
ment for many different combinations of net proliferation rates,
ρ, and net invasion rates, Dw and Dg.
For all cases, treatment was started when the tumor reached a
simulated 1 cm T1Gd radius for a total of 100 continuous days.
Treatment was implemented in the same manner as the first
case. Illustrative results are shown in Figure 6 from simulations
with ρ= [5, 75, 125] (1/year) and Dw= [5.3, 53] (mm2/year) and
Dg=Dw/10 consistent with the observed range hypothesized in
human gliomas (Harpold et al., 2007) and since observed (Wang
et al., 2009; Rockne et al., 2010).
From these six scenarios, summarized in Figure 6, we were able
to observe a few trends. First, none of the simulations showed a sig-
nificant change in the bulk tumor growth rate after treatment had
begun. However, levels of edema were impacted and by different
degrees in each of the simulations. In general, tumors with higher
proliferative capacities (higher ρ’s), due to their higher metabolic
needs, have larger regions of hypoxia and thus produce greater
levels of angiogenic factors. Treatment of these tumors initially
reduces the level of edema, however, the tumor quickly produces
enough angiogenic factors to continue progressing under imaging.
In contrast, the slower growing tumors (low ρ) produce low levels
of angiogenic factors and treatment may result in a complete dis-
appearance of the abnormality on imaging. Additionally, higher
dispersion rates (highDw andDg) reduce the local metabolic needs
and the production of angiogenic factors. Thus, the imaging of
tumors with high Dw and high Dg improve for a longer time,
however, ultimately the tumor does still produce enough angio-
genic factors to be seen progressing on imaging. For all cases, once
treatment is discontinued, the edema levels quickly rise to again
reflect the underlying tumor burden.
What is particularly encouraging is that many of the different
behaviors observed for the four patients illustrated in Figure 2 can
be connected to different simulation predictions. For example, the
first patient’s behavior is analogous to the moderate proliferation
rate with a low invasion rate in that the imageable lesion initially
decreased, stabilized, but after treatment dramatically increased.
Additionally, the second patient can be compared to either the
moderate or highly proliferative rate with a high invasion rate
where the hyperintensity is seen to decrease at the beginning of
treatment, but even while treatment is continuing, start growing
again.
DISCUSSION
Anti-angiogenics remain a controversial form of treatment for
GBM due to the difficulty in assessing tumor response using MR
imaging. The resulting reduction in swelling and related symp-
toms for a subset of patients keeps it an attractive option despite
the lack of evidence of an increase in overall survival and the pos-
sibility of the treatment selecting for a more aggressive phenotype
(Ebos et al., 2009; Pàez-Ribes et al., 2009; Verhoeff et al., 2009;
Keunen et al., 2011). It is unclear how anti-angiogenic treatment
FIGURE 6 | Using the PIHNA-E model, holding all parameters constant
except for D and ρ, one can observe many different responses to
anti-angiogenic treatment in terms of the levels of edema. These
responses vary from complete disappearance of imageable edema to
stabilized lower levels to lowered levels of edema that continue to increase.
When treatment is terminated, however, edema levels are always seen rise
to once again reflect more closely the underlying disease burden.
Treatment times are indicated by the gray boxes. These simulations suggest
that the majority of imaging responses can be explained by considering
how the drug impacts the tumor microenvironment alone without cytotoxic
affects. Additionally, they represent a possible mechanism for identifying
the patients who will receive significant benefit from the treatment.
impacts the cell phenotypes present and there is not yet a deep
enough understanding or a unifying theory to provide explanation
for all the different response patterns. Thus, a priori identifica-
tion of patients who will receive a significant symptom-reduction
benefit remains difficult. As there are other side effects and con-
sequences from anti-angiogenic therapy, being able to make this
early distinction would help remove the controversial nature of
this therapy.
The model developed in this work, built on the PIHNA model
for glioma proliferation and invasion (Swanson et al., 2011; Gu
et al., 2012), is meant to illustrate a first step toward the creation
of a tool for identifying patients who will receive the greatest ben-
efit from anti-angiogenic treatment. It captures the formation of
edema caused by leaky vasculature, and is thus able to decouple
what would be seen on the T2/FLAIR MRI from the true underly-
ing disease burden. In effect, this would help the clinicians to “turn
the light back on” by being able to infer the disease burden that lies
beyond what is captured by imaging alone. While this model is not
meant to capture individual cell behavior, it does provide a map
between overall tumor growth kinetics and treatment response on
the imaging/continuum scale.
Many simplifying assumptions have been made in the cre-
ation of this model such as ignoring the possible direct impact of
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anti-angiogenic therapy on cell proliferation, the likely presence
of thrombosis (Tehrani et al., 2008), and that the hyperinten-
sity on the T2/FLAIR image is entirely a result of fluid leaking
from the vasculature. The model is clearly incomplete, and future
modifications of the model will need to consider these other
phenomena as well as other possible factors on T2/FLAIR hyper-
intensity, such as higher cell density and additional cytoplasm.
However, even in its current state, it has been able to exhibit many
of the types of response patterns observed clinically. It is par-
ticularly encouraging because the modeling effects of treatment
were held constant and only varying the net dispersal and net
proliferation rates, D and ρ, respectively, was sufficient to pro-
duce a wide range of imaging responses analogous to what is
seen clinically. That is, by modeling the treatment in the exact
same way for different values of proliferation and diffusion in
the tumor growth model, the visible levels of edema are seen
to respond in different ways. In general, the simulations predict
edema (swelling) to decrease, supporting the role of these drugs
as surrogates for steroids for reduction of symptoms, analogous
to the most current understanding (Deming, 2012). Though, the
model clearly illustrates that not all patients would receive the
same benefit.
Another interesting implication from these simulations is that
while different imaging responses to treatment were achieved for
the same treatment conditions, in all cases the bulk tumor is seen to
progress with little deflection in overall tumor growth rates. This
result could be considered evidence against the cytotoxic effects
of anti-angiogenic treatment when administered exclusively, also
in agreement with current clinical understanding (Verhoeff et al.,
2009). While this work is not directly speaking to survival out-
comes, we remark that these results highlight the potential for
the mathematical model paradigm to serve in evaluating clinical
trial outcomes by analyzing relative benefit from anti-angiogenics,
especially in the case of low-N trials. As a particular example, such
models may have the potential to be applied to patient cohorts for
exploring how differential effects of anti-angiogenics on imaging
may or may not relate to overall outcomes.
A drawback of this model is the large number of parameters
required. In this document, we assumed the primary influential
factor were the net rates of invasion and proliferation and thus
held all other parameters constant. These other parameters are
likely different patient to patient, however, as demonstrated here,
changes in the small number of parameters are sufficient to pro-
duce a wide variety of imaging responses. While future sensitivity
analysis is required, we believe the work is here is evidence that
a complicated explanation for the different imaging responses to
anti-angiogenic therapy may not be needed. Major next steps of
this work will involve developing techniques for obtaining patient
specific growth parameters from pre-treatment images which we
believe will be successful from previous accomplishments with a
simpler model capturing just the proliferation and invasion tumor
characteristics PI (Swanson, 1999, 2002; Swanson et al., 2000, 2003,
2004, 2008a; Szeto et al., 2009; Wang et al., 2009; Rockne et al.,
2010).
Also, modification of the model to capture the pressure induced
from the vasogenic edema and possible herniation would allow for
deeper understanding of the steroid-like reduction in swelling. For
each new feature eventually added validation tests will be required,
however, we believe the results presented here in and of them-
selves represent a significant step in overcoming clinical imaging
restrictions with mathematical models.
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